1. Home
  2. SLN vs AHH Comparison

SLN vs AHH Comparison

Compare SLN & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • AHH
  • Stock Information
  • Founded
  • SLN 1994
  • AHH 1979
  • Country
  • SLN United Kingdom
  • AHH United States
  • Employees
  • SLN N/A
  • AHH N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • AHH Real Estate
  • Sector
  • SLN Health Care
  • AHH Finance
  • Exchange
  • SLN Nasdaq
  • AHH Nasdaq
  • Market Cap
  • SLN 919.6M
  • AHH 835.5M
  • IPO Year
  • SLN N/A
  • AHH 2013
  • Fundamental
  • Price
  • SLN $18.50
  • AHH $11.17
  • Analyst Decision
  • SLN Strong Buy
  • AHH Buy
  • Analyst Count
  • SLN 4
  • AHH 2
  • Target Price
  • SLN $61.50
  • AHH $11.75
  • AVG Volume (30 Days)
  • SLN 179.3K
  • AHH 957.6K
  • Earning Date
  • SLN 11-12-2024
  • AHH 11-04-2024
  • Dividend Yield
  • SLN N/A
  • AHH 7.34%
  • EPS Growth
  • SLN N/A
  • AHH N/A
  • EPS
  • SLN N/A
  • AHH N/A
  • Revenue
  • SLN $22,623,125.00
  • AHH $735,262,000.00
  • Revenue This Year
  • SLN N/A
  • AHH N/A
  • Revenue Next Year
  • SLN $104.98
  • AHH $3.87
  • P/E Ratio
  • SLN N/A
  • AHH N/A
  • Revenue Growth
  • SLN N/A
  • AHH 23.67
  • 52 Week Low
  • SLN $6.51
  • AHH $9.81
  • 52 Week High
  • SLN $27.72
  • AHH $13.11
  • Technical
  • Relative Strength Index (RSI)
  • SLN 48.92
  • AHH 47.42
  • Support Level
  • SLN $18.20
  • AHH $10.68
  • Resistance Level
  • SLN $19.36
  • AHH $11.35
  • Average True Range (ATR)
  • SLN 0.88
  • AHH 0.20
  • MACD
  • SLN -0.04
  • AHH 0.05
  • Stochastic Oscillator
  • SLN 35.50
  • AHH 73.94

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. They lease our properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting and real estate services. It generates maximum revenue from the general contracting and real estate services segment.

Share on Social Networks: